INTRACRINE DYNAMICS OF CYP17A1 ACTIVITIES IN HUMAN CASTRATION RESISTANT PROSTATE CANCER

被引：0
|
作者：
Kosaka, Takeo
Miyajima, Akira
Maeda, Takahiro
Nagata, Hirohiko
Yasumizu, Yota
Kikuchi, Eiji
Oya, Mototsugu
机构：
来源：
JOURNAL OF UROLOGY | 2013年 / 189卷 / 04期
关键词：
D O I：
10.1016/j.juro.2013.02.1900
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
506
引用
收藏
页码：E207 / E208
页数：2
相关论文
共 50 条
  • [21] Association Between CYP17A1, CYB5A Polymorphisms and Efficacy of Abiraterone Acetate/Prednisone Treatment in Castration-Resistant Prostate Cancer Patients
    Wu, Xiang
    Xu, Qing-Jiang
    Chen, Ping-Zhou
    Yu, Chen-Bo
    Ye, Lie-Fu
    Li, Tao
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2020, 13 : 181 - 188
  • [22] TSPYL GENE FAMILY REGULATES CYP17A1 AND CYP3A4 EXPRESSION: POTENTIAL MECHANISM CONTRIBUTING TO ABIRATERONE RESPONSE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
    Qin, S.
    Liu, D.
    Kohli, M.
    Wang, L.
    Vedell, P.
    Niu, N.
    Yu, J.
    Weinshilboum, R. M.
    Wang, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S16 - S16
  • [23] Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy
    Takeshi Yamada
    Masashi Nakayama
    Tomohito Shimizu
    Shinpei Nonen
    Yasutomo Nakai
    Kazuo Nishimura
    Yasushi Fujio
    Akihiko Okuyama
    Junichi Azuma
    Norio Nonomura
    International Journal of Clinical Oncology, 2013, 18 : 711 - 717
  • [24] NEUROPEPTIDES PROMOTE CASTRATION RESISTANT PROSTATE CANCER THROUGH INTRACRINE ANDROGEN BIOSYNTHESIS
    Evans, Chris
    Yang, Joy
    Kung, Hsing-Jien
    Gao, Allen
    JOURNAL OF UROLOGY, 2011, 185 (04): : E109 - E109
  • [25] Discovery and development of ODM-204: A Novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1
    Oksala, Riikka
    Moilanen, Anu
    Riikonen, Reetta
    Rummakko, Petteri
    Karjalainen, Arja
    Passiniemi, Mikko
    Wohlfahrt, Gerd
    Taavitsainen, Paivi
    Malmstrom, Chira
    Ramela, Meri
    Metsankyla, Hanna-Maija
    Huhtaniemi, Riikka
    Kallio, Pekka J.
    Mustonen, Mika V. J.
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2019, 192
  • [26] Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy
    Yamada, Takeshi
    Nakayama, Masashi
    Shimizu, Tomohito
    Nonen, Shinpei
    Nakai, Yasutomo
    Nishimura, Kazuo
    Fujio, Yasushi
    Okuyama, Akihiko
    Azuma, Junichi
    Nonomura, Norio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (04) : 711 - 717
  • [27] Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
    Toren, Paul J.
    Kim, Soojin
    Pham, Steven
    Mangalji, Azzra
    Adomat, Hans
    Guns, Emma S. Tomlinson
    Zoubeidi, Amina
    Moore, William
    Gleave, Martin E.
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (01) : 59 - 69
  • [28] ODM-204: A novel dual inhibitor of CYP17A1 and androgen receptor for the treatment of castration-resistant prostate cancer-Preclinical data.
    Oksala, Riikka
    Moilanen, Anu
    Riikonen, Reetta
    Rummakko, Petteri
    Huhtaniemi, Riikka
    Kallio, Pekka
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [29] Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis
    Udhane, Sameer S.
    Dick, Bernhard
    Hu, Qingzhong
    Hartmann, Rolf W.
    Pandey, Amit V.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 477 (04) : 1005 - 1010
  • [30] Friedelin, a novel inhibitor of CYP17A1 in prostate cancer from Cassia tora
    Joshi, Bhrugesh Pravinchandra
    Bhandare, Vishwambhar Vishnu
    Vankawala, Mahima
    Patel, Prittesh
    Patel, Rajesh
    Vyas, Bhavin
    Krishnamurty, Ramar
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (19): : 9695 - 9720
12345